Join
Live feed
·
INSIDERFilingvia Quantisnow
MoonLake Immunotherapeutics logo

Chief Financial Officer Bodenstedt Matthias sold $351,576 worth of Class A ordinary shares (17,876 units at $19.67) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,154,555 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
MLTX· MoonLake Immunotherapeutics
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MLTX (MoonLake Immunotherapeutics) and more on Quantisnow.